Abbvie Biotherapeutics Inc.

Scios Inc.

Abbview Biotherapeutics Inc.

Taymar E Hartman

J Yun Tso

Ping Y Huang

Paul W Sauer

Braeden D Partridge

John E Burky

Mark C Wesson

Thomas J Robinson

Ziyang Zhong

Douglas I Buckley

N Stephen Pollitt

Peter A Stathis

Yimin He

The present disclosure is directed to expression vectors, comprising a weakened SV40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells.

Vectors and host cells comprising a modified SV40 promoter for protein expression

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.

DAC HYP compositions

DAC HYP compositions and methods

A method is described for producing a peptide having a pI above 8 or below 5 wherein the peptide is expressed as a fusion protein in which it is linked to a fusion partner through an acid cleavage site. The peptide is released from the fusion partner by acid cleavage in the absence of chaotrope. The fusion partner and its acid cleavage products, if any, have a net charge sufficiently different from that of the desired peptide to allow isolation of the peptide by ion-exchange chromatography.

Method for producing a peptide with a pI above 8 or below 5

Growing community of inventors

Redwood City, CA, United States of America

Taymar E Hartman